Related Experiment Video
Updated: Jun 24, 2026
08:27
Real-time Cytotoxicity Assays in Human Whole Blood
Published on: November 7, 2014
[Anti-CD20 in hematologic oncology]
1Service des maladies du sang, CHU de Bordeaux, Université Bordeaux 2 Victor Segalen, F-33600 Pessac Cedex, France. noel.milpied@chu-bordeaux.fr
Presse Medicale (Paris, France : 1983)
|March 20, 2009
Summary
Rituximab, an anti-CD20 antibody, has significantly improved survival for B cell lymphomas like follicular lymphoma. It is now a standard treatment, alone or with chemotherapy, for various lymphoma types and relapses.
Area of Science:
- Oncology
- Immunology
- Hematology
Context:
- Rituximab, a chimeric monoclonal anti-CD20 antibody, has been available for twelve years.
- It has improved survival by approximately 20% for most B cell lymphomas.
Purpose:
- To review the established and evolving role of rituximab in treating various B cell lymphomas.
- To highlight its efficacy as first-line treatment, for relapses, and as maintenance therapy.
Summary:
- Rituximab combined with chemotherapy is the first-line treatment for follicular lymphoma when necessary.
- It is also effective for relapses and as maintenance therapy, improving relapse-free and overall survival.
- Standard treatment for high-grade diffuse lymphoma and a reference for chronic lymphoid leukemia now includes rituximab.
Impact:
- Rituximab has become a cornerstone in treating B cell lymphomas, improving patient outcomes.
- Its use has led to the development of new-generation anti-CD20 antibodies.
- The evaluation of rituximab in more severe lymphoma forms is ongoing.
